Telbolife ACH Tablet is a comprehensive antihypertensive formulation designed to provide effective and long-lasting control of high blood pressure in patients requiring combination therapy. It brings together three well-established agents—Telmisartan, Amlodipine, and Chlorthalidone—each targeting a different mechanism involved in the pathogenesis of hypertension. This combination offers enhanced efficacy in managing resistant or uncontrolled hypertension and reduces the risk of long-term cardiovascular complications.
Telmisartan (40 mg) is an angiotensin II receptor blocker (ARB) that works by blocking the vasoconstrictive and aldosterone-secreting actions of angiotensin II, thereby relaxing blood vessels and lowering blood pressure.
Amlodipine (5 mg) is a long-acting calcium channel blocker that inhibits calcium influx into vascular smooth muscles, resulting in vasodilation and reduced peripheral resistance.
Chlorthalidone (12.5 mg) is a thiazide-like diuretic that helps lower blood pressure by promoting the elimination of excess sodium and water, effectively reducing blood volume and vascular stiffness.
The synergistic effect of these three agents offers superior blood pressure control compared to monotherapy or dual therapy, especially in patients with moderate to severe hypertension. Telbolife ACH Tablet is suitable for individuals who require triple therapy for optimal blood pressure management and for reducing the risk of stroke, heart attack, and renal impairment.
This fixed-dose combination is convenient for once-daily administration and improves patient adherence. It is particularly beneficial for patients with comorbidities such as diabetes, obesity, or chronic kidney disease, where tight blood pressure control is critical.
Patients are advised to maintain a healthy lifestyle alongside medication use, including a low-sodium diet, regular physical activity, weight management, and avoiding smoking and alcohol.